-
1
-
-
78049488759
-
Bortezomib plus dexamethasone is superior to vincristine plus doxorubicin plus dexamethasone as induction treatment prior to autologous stem-cell transplantation in newly diagnosed multiple myeloma: Results of the IFM 2005-01 Phase III trial
-
Harousseau JL, Attal M, Avet-Loiseau H, et al. Bortezomib plus dexamethasone is superior to vincristine plus doxorubicin plus dexamethasone as induction treatment prior to autologous stem-cell transplantation in newly diagnosed multiple myeloma: results of the IFM 2005-01 Phase III trial. J Clin Oncol 2010;28(30):4621-9
-
(2010)
J Clin Oncol
, vol.28
, Issue.30
, pp. 4621-4629
-
-
Harousseau, J.L.1
Attal, M.2
Avet-Loiseau, H.3
-
2
-
-
70350433797
-
The role of complete response in multiple myeloma
-
Harousseau JL, Attal M, Avet-Loiseau H. The role of complete response in multiple myeloma. Blood 2009;114(15):3139-46
-
(2009)
Blood
, vol.114
, Issue.15
, pp. 3139-46
-
-
Harousseau, J.L.1
Attal, M.2
Avet-Loiseau, H.3
-
3
-
-
36349031205
-
Complete response correlates with long-term survival and progression-free survival in high-dose therapy in multiple myeloma
-
DOI 10.3324/haematol.11534
-
van de Velde HJ, Liu X, Chen G, et al. Complete response correlates with long-term survival and progression-free survival in high-dose therapy in multiple myeloma. Haematologica 2007;92(10):1399-406 (Pubitemid 350144158)
-
(2007)
Haematologica
, vol.92
, Issue.10
, pp. 1399-1406
-
-
Van De Velde, H.J.K.1
Liu, X.2
Chen, G.3
Cakana, A.4
Deraedt, W.5
Bayssas, M.6
-
4
-
-
37249040444
-
Benefit of complete response in multiple myeloma limited to high-risk subgroup identified by gene expression profiling
-
DOI 10.1158/1078-0432.CCR-07-0527
-
Haessler J, Shaughnessy JD Jr, Zhan F, et al. Benefit of complete response in multiple myeloma limited to high-risk subgroup identified by gene expression profiling. Clin Cancer Res 2007;13(23):7073-9 (Pubitemid 350276890)
-
(2007)
Clinical Cancer Research
, vol.13
, Issue.23
, pp. 7073-7079
-
-
Haessler, J.1
Shaughnessy Jr., J.D.2
Zhan, F.3
Crowley, J.4
Epstein, J.5
Van Rhee, F.6
Anaissie, E.7
Pineda-Roman, M.8
Zangari, M.9
Hollmig, K.10
Mohiuddin, A.11
Alsayed, Y.12
Hoering, A.13
Tricot, G.14
Barlogie, B.15
-
5
-
-
78650303638
-
Phase III intergroup study of lenalidomide versus placebo maintenance therapy following single autologous stem cell transplant (ASCT) for multiple myeloma (MM): CALGB 100104
-
McCarthy PL, Owzar K, Anderson KC, et al. Phase III intergroup study of lenalidomide versus placebo maintenance therapy following single autologous stem cell transplant (ASCT) for multiple myeloma (MM): CALGB 100104. ASCO Meeting Abstracts. 2010;28(15 Suppl):8017
-
(2010)
ASCO Meeting Abstracts
, vol.28
, Issue.15 SUPPL.
, pp. 8017
-
-
McCarthy, P.L.1
Owzar, K.2
Anderson, K.C.3
-
6
-
-
79952836604
-
Maintenance treatment with lenalidomide after transplantation for MYELOMA: Final analysis of the IFM 2005-02
-
ASH Annual Meeting Abstracts
-
Attal M, Lauwers Vc, Marit G, et al. Maintenance treatment with lenalidomide after transplantation for MYELOMA: Final analysis of the IFM 2005-02. ASH Annual Meeting Abstracts. Blood 2010;116(21):310
-
(2010)
Blood
, vol.116
, Issue.21
, pp. 310
-
-
Attal, M.1
Lauwers, V.C.2
Marit, G.3
-
7
-
-
77955980661
-
Bortezomib Plus Dexamethasone (VD) Versus Reduced-dose bortezomib Plus Thalidomide Plus Dexametasone (vTD) as Induction Treatment Prior to Autologous Stem-Cell Transplantation (ASCT) in Newly Diagnosed Multiple Myeloma (MM)
-
Harousseau J-L, Avet-Loiseau H, Facon T, et al. Bortezomib Plus Dexamethasone (VD)Versus Reduced-dose bortezomib Plus Thalidomide Plus Dexametasone (vTD) as Induction Treatment Prior to Autologous Stem-Cell Transplantation (ASCT) in Newly Diagnosed Multiple Myeloma (MM). ASH Annual Meeting Abstracts 2009;114(22):354
-
(2009)
ASH Annual Meeting Abstracts
, vol.114
, Issue.22
, pp. 354
-
-
Harousseau, J.-L.1
Avet-Loiseau, H.2
Facon, T.3
-
8
-
-
79952790841
-
HOVON-65/GMMG-HD4 Randomized Phase III Trial Comparing Bortezomib, Doxorubicin, Dexamethasone (PAD) Vs VAD Followed by High-Dose Melphalan (HDM) and Maintenance with Bortezomib or Thalidomide in Patients with Newly Diagnosed Multiple Myeloma (MM)
-
Sonneveld P, Schmidt-Wolf I, van der Holt B, et al. HOVON-65/GMMG-HD4 Randomized Phase III Trial Comparing Bortezomib, Doxorubicin, Dexamethasone (PAD) Vs VAD Followed by High-Dose Melphalan (HDM) and Maintenance with Bortezomib or Thalidomide In Patients with Newly Diagnosed Multiple Myeloma (MM). ASH Annual Meeting Abstracts 2010;116(21):40
-
(2010)
ASH Annual Meeting Abstracts
, vol.116
, Issue.21
, pp. 40
-
-
Sonneveld, P.1
Schmidt-Wolf, I.2
Van Der Holt, B.3
-
9
-
-
77955452192
-
Velcade Intravenous Cyclophosphamide and Dexamethasone (VCD) Induction for Previously Untreated Multiple Myeloma (German DSMM XIa Trial)
-
Einsele H, Liebisch P, Langer C, et al. Velcade, Intravenous Cyclophosphamide and Dexamethasone (VCD) Induction for Previously Untreated Multiple Myeloma (German DSMM XIa Trial). ASH Annual Meeting Abstracts 2009;114(22):131
-
(2009)
ASH Annual Meeting Abstracts
, vol.114
, Issue.22
, pp. 131
-
-
Einsele, H.1
Liebisch, P.2
Langer, C.3
-
10
-
-
67650882695
-
Cyclophosphamide, bortezomib and dexamethasone induction for newly diagnosed multiple myeloma: High response rates in a Phase II clinical trial
-
Reeder CB, Reece DE, Kukreti V, et al. Cyclophosphamide, bortezomib and dexamethasone induction for newly diagnosed multiple myeloma: high response rates in a Phase II clinical trial. Leukemia 2009;23(7):1337-41
-
(2009)
Leukemia
, vol.23
, Issue.7
, pp. 1337-41
-
-
Reeder, C.B.1
Reece, D.E.2
Kukreti, V.3
-
11
-
-
77954618168
-
Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma
-
Richardson PG, Weller E, Lonial S, et al. Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma. Blood 2010;116(5):679-86
-
(2010)
Blood
, vol.116
, Issue.5
, pp. 679-86
-
-
Richardson, P.G.1
Weller, E.2
Lonial, S.3
-
12
-
-
77954660886
-
Bortezomib, dexamethasone, cyclophosphamide and lenalidomide combination for newly diagnosed multiple myeloma: Phase 1 results from the multicenter evolution study
-
Kumar SK, Flinn I, Noga SJ, et al. Bortezomib, dexamethasone, cyclophosphamide and lenalidomide combination for newly diagnosed multiple myeloma: Phase 1 results from the multicenter evolution study. Leukemia 2010;24(7):1350-6
-
(2010)
Leukemia
, vol.24
, Issue.7
, pp. 1350-6
-
-
Kumar, S.K.1
Flinn, I.2
Noga, S.J.3
|